SynthesisPituitary2024
Quality of life in Prolactinoma: A systematic review.
Synthesis in Pituitary, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- How to Define Success in Prolactinoma Treatment-A Systematic Review and Theoretical Framework.The Journal of clinical endocrinology and metabolism · 2026Pooled it
- Frailty and pituitary surgery: a systematic review.Pituitary · 2025Pooled it
- Quality of life in non-functioning pituitary adenoma: A systematic review.Neurosurgical review · 2024Pooled it
- Determinants of quality of life following resection of skull base tumors: a systematic review.Frontiers in oncology · 2024Pooled it
- Chinese consensus on the diagnosis and treatment of prolactinomas (2025 edition).Chinese neurosurgical journal · 2026Review
- Patient-reported outcomes in a Pituitary Tumor Center of Excellence (PTCOE)-aligned pituitary clinic compared with general endocrinology care.Pituitary · 2026Article
- Health-related quality of life in women with normogonadotropic ovulatory dysfunction: a prospective cohort study.Frontiers in global women's health · 2026Article
- Subtle Cognitive Impairments and Psychological Complaints in Patients With Prolactinoma Despite Biochemical Control.The Journal of clinical endocrinology and metabolism · 2025Article
- Correlation between serum endocrine hormone levels and malignancy degree of prolactinoma and their predictive value for patient prognosis.Scientific reports · 2025Article
- A Narrative Review of Surgery for Prolactinomas: Considerations and Controversies.Journal of clinical medicine · 2025Review
- Exploring sex-specific hematological changes and their impact on quality of life in patients with prolactinoma.Pituitary · 2025Article
- Psychological burden in patients with sellar masses under conservative and surgical management.Neurosurgical review · 2025Article
- Wogonin inhibits the proliferation of prolactinoma through the PI3K/AKT signaling pathway.Frontiers in pharmacology · 2025Article
- Sleep quality during preparation for RAI: recombinant TSH vs. levothyroxine withdrawal.Frontiers in endocrinology · 2025Article
- Modern approach to bone comorbidity in prolactinoma.Pituitary · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundProlactinomas are common tumours that significantly reduce quality-of-life (QOL) due to sellar mass effect, secondary hypogonadism, and the peripheral effects of prolactin. Understanding the factors that influence QOL would provide insights into therapeutic targets to optimise patient outcomes and improve wellbeing in prolactinoma.
methodsA systematic review was performed in accordance with the PRISMA statement. Studies that reported patient QoL using validated metrics were included. Bias and methodological rigour were assessed using the MINORS criteria.
resultsA total of 18 studies were identified studies were available for review, comprising 877 patients. Most were small cross-sectional studies at high risk of bias. Prolactinoma exhibit worse QOL than healthy controls, particularly mental and psychosocial wellbeing. QOL is also worse than patients with non-functional adenomas, but better than those with Cushing's disease and acromegaly. QOL correlates with prolactin levels, and approaches population baseline with prolonged biochemical control. Dopamine agonists and surgery both improve overall QOL, however improvements are more rapid with surgery.
conclusionPoor quality of life in prolactinoma is multifactorial, related to biochemical control, side effects of therapy, and sellar mass effect. Targeting persistent symptoms, reducing healthcare costs, and reducing side-effects of therapy are avenues to improving QOL in patients with prolactinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.